Misplaced Pages

BMS-955176

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
BMS-955176
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC42H62N2O4S
Molar mass691.03 g·mol
3D model (JSmol)
SMILES
  • CC(=C)1CC2(13CC4(3(CC2)C)(CC54(CC=C(C5(C)C)c6ccc(cc6)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7
InChI
  • InChI=1S/C42H62N2O4S/c1-28(2)31-14-19-42(43-22-23-44-24-26-49(47,48)27-25-44)21-20-40(6)33(36(31)42)12-13-35-39(5)17-15-32(29-8-10-30(11-9-29)37(45)46)38(3,4)34(39)16-18-41(35,40)7/h8-11,15,31,33-36,43H,1,12-14,16-27H2,2-7H3,(H,45,46)/t31-,33+,34-,35+,36+,39-,40+,41+,42-/m0/s1
  • Key:XDMUFNNPLXHNKA-ZTESCHFWSA-N

BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells. First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been designed to better tolerate gag polymorphisms.

Studies

Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI). Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.

It appears that development of BMS-955176 has been terminated.

See also

References

  1. "BMS Maturation Inhibitor Is Potent Against HIV in Early Trial". 25 February 2015. Archived from the original on 23 July 2015. Retrieved 22 July 2015.
  2. "CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform".
  3. Wang D, Lu W, Li F (November 2015). "Pharmacological intervention of HIV-1 maturation". Acta Pharmaceutica Sinica B. 5 (6): 493–9. doi:10.1016/j.apsb.2015.05.004. PMC 4675807. PMID 26713265.
  4. ^ "Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor | CROI Conference". www.croiconference.org. Retrieved 2016-01-01.
  5. "HIV maturation inhibitor BMS-955176 looks promising in early study". www.aidsmap.com. Retrieved 2016-01-01.
  6. "GSK Discontinues Development of Maturation Inhibitor BMS-955176".
Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Capsid inhibitors
Entry/fusion inhibitors
(Discovery and development)
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))
Maturation inhibitors
Protease Inhibitors (PI)
(Discovery and development)
1 generation
2 generation
Reverse-transcriptase
inhibitors (RTIs)
Nucleoside and
nucleotide (NRTI)
Non-nucleoside (NNRTI)
(Discovery and development)
1 generation
2 generation
Combined formulations
Pharmacokinetic boosters
Experimental agents
Uncoating inhibitors
Transcription inhibitors
Translation inhibitors
BNAbs
Other
Failed agents
°DHHS recommended initial regimen options. Formerly or rarely used agent.
Categories: